Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 30, 2026

Schneider National outlines $0.70–$1 EPS guidance for 2026 with $40M in new cost savings and executive transition amid industry supply attrition

View original at seekingalpha.com
Schneider National outlines $0.70–$1 EPS guidance for 2026 with $40M in new cost savings and executive transition amid industry supply attrition Earnings Call Insights: Schneider National (SNDR) Q4 2025 MANAGEMENT VIEW * CEO Mark Rourke opened the call by stating, "the fourth quarter results fell short of our expectati…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Network has been most impacted by the cycle and overcapacity of the market, requiring combination of productivity and price recovery levers

    80% confidence
  • Automotive shutdown impact was an emerging issue that a number of OEMs had to work through

    80% confidence
  • Q4 adjusted income from operations was $38 million, a decline of 15% compared to a year ago

    80% confidence
  • Momentum will continue in 2026 with an additional $40 million of cost savings

    80% confidence
  • Full year 2026 adjusted EPS guidance is $0.70 to $1.00, assuming effective tax rate of approximately 24%, with anticipated stronger second half

    80% confidence
  • In all points of guidance, expecting supply to continue to exit the market

    80% confidence
  • Company is not simply waiting for improved cycle dynamics

    80% confidence
  • Schneider has grown Dedicated offerings to nearly 70% of fleet, increasing durability and resilience of Truckload segment

    80% confidence
  • Strategic momentum for 2026 includes ramping synergies in acquired companies, leading Intermodal growth including Intermodal Fast Track service, heavy Dedicated start-up activity and Network earnings improvement

    80% confidence
  • Despite challenging market in 2025, actions throughout the year have strengthened foundation and positioned company to benefit as conditions improve, with early signs of improving market conditions as supply rationalization is underway

    80% confidence
  • The fourth quarter results fell short of expectations due to materially more challenged November and December than guidance contemplated, reflecting a very truncated peak season and poor weather conditions throughout the Midwest

    80% confidence
  • Company achieved targeted $40 million of cost savings in 2025, including synergies from Common Systems acquisition

    80% confidence
  • Q4 revenues excluding fuel surcharge were $1.3 billion, up 4% year-over-year

    80% confidence
  • There was some restocking activity attempting to take place in last couple of weeks of December, some pushed into January, and company is working through that backlog

    80% confidence
  • Dedicated revenue per truck per week decline attributed to automotive shutdowns due to componentry issues around chips and 3 large start-ups

    80% confidence
  • Company expects to continue to lean into price because price recovery is part of what needs to occur to get back to mid-cycle earnings targets

    80% confidence
  • Environment is characterized by both inflationary cost pressure and demand uncertainty

    80% confidence
  • CapEx plan for 2026 is mostly replacement based, given focus on keeping fleet count flat

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com
Schneider National outlines $0.70–$1 EPS guidance for 2026 with $40M in new cost savings and executive transition amid industry supply attrition — Source | Via News | ViaNews EU